Epidemiology of HIV-Associated Malignancies

  • Luigino Dal Maso
  • Diego Serraino
  • Silvia Franceschi
Part of the Cancer Treatment and Research book series (CTAR, volume 104)


Immunodeficiency, whether congenital or acquired, increases the risk of certain, but not all, types of cancer. The study of cancer in the HIV-infected population offers a unique opportunity to investigate on an unprecedented large scale the role of the immune system in the onset and growth of tumours.


Human Immunodeficiency Virus Human Immunodeficiency Virus Type Anal Cancer Acquir Immune Multicenter AIDS Cohort Study 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    IARC Working Group on the Evaluation of Carcinogenic Risks to Humans: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Human immunodeficiency Viruses and Human T-Cell Lymphotropic Viruses. Vol. 67, Lyon, IARC, 1996.Google Scholar
  2. 2.
    Biggar RI, Horm J, Goedert JJ, Melbye M: Cancer in a group at risk of acquired immunodeficiency syndrome (AIDS) through 1984. Am J Epidemiol 126:578–586, 1987.PubMedGoogle Scholar
  3. 3.
    Biggar RI, Rosenberg PS, Coté T: Kaposi’s sarcoma and non-Hodgkin’s lymphoma following the diagnosis of AIDS. Int J Cancer 68: 754–758, 1996PubMedCrossRefGoogle Scholar
  4. 4.
    Goedert JJ, Coté TR, Virgo P: Spectrum of AIDS-associated malignant disorders. Lancet 351: 1833–1839, 1998PubMedCrossRefGoogle Scholar
  5. 5.
    Franceschi S, Dal Maso L, Armani S, et al: Risk of cancer other than Kaposi’s sarcoma and non-Hodgkin’s lymphoma in persons with AIDS in Italy. Br J Cancer 78:966–970, 1998PubMedCrossRefGoogle Scholar
  6. 6.
    Grulich AE, Wan X, Law MG, et al: Risk of cancer in people with AIDS. AIDS 13: 839–843,1999PubMedCrossRefGoogle Scholar
  7. 7.
    Franceschi S, Geddes M: Epidemiology of classic Kaposi’s sarcoma, with special reference to Mediterranean population. Tumori 81:308–314, 1995PubMedGoogle Scholar
  8. 8.
    Franceschi S, Dal Maso L, Lo Re A, et al: Trends of Kaposi’s sarcoma at AIDS diagnosis in Europe and the United States, 1987–94. Br J Cancer 76:114–117, 1997PubMedCrossRefGoogle Scholar
  9. 9.
    Chang Y, Cesarman E, Pessin MS, et al: Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science 265:1865–1869, 1994CrossRefGoogle Scholar
  10. 10.
    Boshoff C: Kaposi’s sarcoma associated herpesvirus. in Newton R, Beral V, Weiss RA (eds): Infections and Human Cancer. Cancer Surveys Vol. 33:157–190, 1999Google Scholar
  11. 11.
    Gao SJ, Kingsley L, Li M, et al. KSHV antibodies among Americans, Italians, and Ugandans with and without Kaposi’s sarcoma. Nat Med 2: 925–928, 1996PubMedCrossRefGoogle Scholar
  12. 12.
    Melbye M, Cook PM, Hjalgrim H, et al: Risk factors for Kaposi’s-sarcomaassociated herpesvirus (KSHV/HHV-8) seropositivity in a cohort of homosexual men, 1981–1996. Int J Cancer 77:543–548, 1998PubMedCrossRefGoogle Scholar
  13. 13.
    ENAADS European Centre for the Epidemiological Monitoring of AIDS: HIV/AIDS Surveillance in Europe. Quarterly Report No. 60, AIDS Cases Report by 31 December 1998. Saint-Maurice, France, Hôpital National de Saint-Maurice, 1998Google Scholar
  14. 14.
    Dal Maso L, Franceschi S, Negri E, et al: Trends of AIDS incidence in Europe and the United States. Soz Präventivmed 40:239–265, 1995CrossRefGoogle Scholar
  15. 15.
    Koblin BA, Hessol NA, Zauber AG, et al: Increased incidence of cancer among homosexual men, New York City and San Francisco, 1978–1990. Am J Epidemiol 144: 916–923, 1996PubMedCrossRefGoogle Scholar
  16. 16.
    Rabkin CS, Yellin F: Cancer incidence in a population with a high prevalence of infection with human immunodeficiency virus type I. J Natl Cancer Inst 86:1711–1716, 1994PubMedCrossRefGoogle Scholar
  17. 17.
    Lyter DW, Bryant J, Thackeray R, et al: Non-AIDS defining malignancies in the multicenter AIDS cohort study (MACS), 1984–96. J Acquir Immune Defic Syndr Hum Retrovirol 17: A13, 1998 (abstr).CrossRefGoogle Scholar
  18. 18.
    Selik RM, Rabkin, CS: Cancer death rates associated with human immunodeficiency virus infection in the United States. J Natl Cancer Inst 90: 1300–302, 1998PubMedCrossRefGoogle Scholar
  19. 19.
    Serraino D, Franceschi S: Kaposi’s sarcoma in children with AIDS in Europe and the United States. Eur J Cancer 32A:650–651, 1996PubMedCrossRefGoogle Scholar
  20. 20.
    Dal Maso L, Parazzini F, Lo Re A, et al: Paediatric AIDS incidence in Europe and the USA, 1985–96. J Epidemiol Biostat 4:75–81, 1999Google Scholar
  21. 21.
    Granovsky MO, Mueller BU, Nicholson HS, et al: Cancer in human immunodeficiency virus-infected children: a case series from the Children’s Cancer Group and the National Cancer Institute. J Clin Oncol 16: 1729–1735, 1998PubMedGoogle Scholar
  22. 22.
    Wabinga HR, Parkin DM, Wabwire-Mangen F, et al: Cancer in Kampala, Uganda, in 1989–91: changes in incidence in the era of AIDS. Int J Cancer 54: 26–36, 1993PubMedCrossRefGoogle Scholar
  23. 23.
    Bassett MT, Chokunonga E, Mauchaza B, et al: Cancer in the African population of Harare, Zimbabwe, 1990–1992. Int J Cancer 63: 29–36, 1995PubMedCrossRefGoogle Scholar
  24. 24.
    Newton R, Grulich A, Beral V, et al: Cancer and HIV infection in Rwanda. Lancet i: 1378, 1995 (letter)CrossRefGoogle Scholar
  25. 25.
    Sitas F, Bezwoda WR, Levin V, et al: Association between human immunodeficiency virus type 1 infection and cancer in the black population of Johannesburg and Soweto, South Africa. Br J Cancer 75: 1704–1707, 1997PubMedCrossRefGoogle Scholar
  26. 26.
    Kinlen L: Immunologic factors, including AIDS, in Schottenfeld D, Fraumeni JF (eds): Cancer Epidemiology and Prevention, 2ndedn. New York, Oxford University Press, 1996, pp 532–545Google Scholar
  27. 27.
    IARC Working Group on the Evaluation of Carcinogenic Risks to Humans: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Epstein-Barr virus and Kaposi’s sarcoma herpesvirus/human herpesvirus 8. Vol. 70, Lyon, IARC, 1997Google Scholar
  28. 28.
    Franceschi S, Dal Maso L, La Vecchia C: Advance in the epidemiology of HIV-associated non-Hodgkin’s lymphoma and other lymphoid neoplasms. Int J Cancer 83: 481–485, 1999PubMedCrossRefGoogle Scholar
  29. 29.
    Coté TR, Biggar RJ, Rosenberg, P, et al: Non-Hodgkin’s lymphoma among people with AIDS: incidence, presentation and public health burden. Int J Cancer 73: 645650, 1997.Google Scholar
  30. 30.
    Serraino D, Pezzotti P, Dorrucci M, et al: Cancer incidence in a cohort of Human Immunodeficiency Virus seroconverters. Cancer 79: 1004–1008, 1997PubMedCrossRefGoogle Scholar
  31. 31.
    Mueller BU: Cancer in children infected with the human immunodeficiency virus. Oncologist 4: 309–317, 1999PubMedGoogle Scholar
  32. 32.
    Kingma DW, Weiss A, Sorbara L, et al: Is lymphocytic interstitial pneumonitis and early stage of MALT lymphoma in HIV- infected pediatric patients? J Acquir Immune Defic Syndr Hum Retrovirol 14: A54, 1997 (abstr)CrossRefGoogle Scholar
  33. 33.
    Newton R, Ngilimana P-J, Grulich A, et al: Cancer in Rwanda. Int J Cancer 66: 7581, 1996CrossRefGoogle Scholar
  34. 34.
    Serraino D, Carrieri P, Pradier C, et al: Risk of invasive cervical among women with, or at risk for, HIV infection. Int J Cancer 82: 334–337, 1999PubMedCrossRefGoogle Scholar
  35. 35.
    Parazzini F, Chatenoud L, La Vecchia C, et al: Determinants of risk of invasive cervical cancer in young women. Br J Cancer, 77, 838–841, 1998PubMedCrossRefGoogle Scholar
  36. 36.
    Patil P, Elem B, Zumla A: Pattern of adult malignancies in Zambia (1980–1989) in the light of the human immunodeficiency virus type 1 epidemic. J Trop Med Hyg 98:281–284, 1995PubMedGoogle Scholar
  37. 37.
    IARC Working Group on the Evaluation of Carcinogenic Risks to Humans: IARC Monographs on the Evaluation of Carcinogenic Risks for Humans from the Human Papillomaviruses. Vol. 64, Lyon, IARC, 1995Google Scholar
  38. 38.
    Breese PL, Judson FN, Penley KA, et al: Anal human papillomavirus infection among homosexual and bisexual men: prevalence of type-specific infection and association with human immunodeficiency virus. Sex Transm Dis 22:7–14, 1995PubMedCrossRefGoogle Scholar
  39. 39.
    Palefsky JM: Anal human papillomavirus infection and anal cancer in HIV-positive individuals: an emerging problem. AIDS 8:283–295, 1994PubMedCrossRefGoogle Scholar
  40. 40.
    Goldman S, Glimelius B, Nilsson B, et al: Incidence of anal epidermoid carcinoma in Sweden, 1970–1984. Acta Chir Scand 155: 191–197, 1989PubMedGoogle Scholar
  41. 41.
    Frisch M, Melbye M, Moller H: Trends in incidence of anal cancer in Denmark. Br Med J 306:419–422, 1993CrossRefGoogle Scholar
  42. 42.
    Melbye M, Coté TR, Kessler L, et al: High incidence of anal cancer among AIDS patients. Lancet 343: 636–639, 1994PubMedCrossRefGoogle Scholar
  43. 43.
    Melbye M, Rabkin C, Frisch M, et al: Changing patterns of anal cancer incidence in the United States, 1940–1989. Am J Epidemiol 139: 772–780, 1994PubMedGoogle Scholar
  44. 44.
    Rabkin CS, Biggar RJ, Horm JW: Increasing incidence of cancers associated with the Human Immunodeficiency Virus epidemic. Int J Cancer 47:692–696, 1991PubMedCrossRefGoogle Scholar
  45. 45.
    Serraino D, Boschini A, Carrieri P, et al: Cancer risk among men with, or at risk for, HIV infection in southern Europe. AIDS submittedGoogle Scholar
  46. 46.
    Vaccher E, Tirelli U, Spina M: Lung cancer in 19 patients with HIV infection. Ann Oncol 4:85–86, 1993PubMedGoogle Scholar
  47. 47.
    Parker MS, Leveno DM, Campbell TJ, et al: AIDS-related bronchogenic carcinoma: fact or fiction? Chest 113:154–161, 1998PubMedCrossRefGoogle Scholar
  48. 48.
    Monfardini S, Vaccher E, Pizzocaro G, et al: Unusual malignant tumours in 49 patients with HIV infection. AIDS 3: 449–452, 1989PubMedCrossRefGoogle Scholar
  49. 49.
    Newton R, Beral V, Weiss RA: Human Immunodeficiency Virus infection and cancer. In: Newton R, Beral V, Weiss RA (eds): Infections and Human Cancer. Cancer Surveys Vol. 33:237–262, 1999Google Scholar
  50. 50.
    Newton R, Ziegler J, Mbidde E, et al: HIV and cancer in Kampala, Uganda. J Acquir Immune Defic Syndr Hum Retrovirol 17: Al2, 1998 (abstr)CrossRefGoogle Scholar
  51. 51.
    Ho DD. Time to hit HIV, early and hard (editorial). N Eng J Med 333: 450–451, 1995.CrossRefGoogle Scholar
  52. 52.
    Feinberg MB, Carpenter C, Fauci AS, et al. Report of the NIH panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Ann Intern Med 128: 1057–1100, 1998.Google Scholar
  53. 53.
    Moore RD, Chiasson RE: Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS 13: 1933–1942, 1999PubMedCrossRefGoogle Scholar
  54. 54.
    Palella FJ, Delaney KM, Moorman AC, et al: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 338: 853–860, 1998PubMedCrossRefGoogle Scholar
  55. 55.
    Mocroft A, Vella S, Benfield TL, et al: Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 352: 1725–1730, 1998PubMedCrossRefGoogle Scholar
  56. 56.
    Jacobson LP, Yamashita TE, Detels R, et al: Impact of potent antiretroviral therapy on the incidence of Kaposi’s sarcoma and non-Hodgkin’s lymphomas among HIV-1infected individuals. J Acquir Immune Defic Syndr 21(suppl.1): S34–S41, 1999PubMedGoogle Scholar
  57. 57.
    Rabkin CS, Testa MA, Huang J, et al: Kaposi’s sarcoma and non-Hodgkin’s lymphoma incidence trends in AIDS Clinical Trial Group study participants. J Acquir Immune Defic Syndr 21(suppl.1): S31–S33, 1999PubMedGoogle Scholar
  58. 58.
    Jones JL, Hanson DL, Dworkin MS, et al: Effect of antiretroviral therapy on recent trends in selected cancers among HIV-infected persons. J Acquir Immune Defic Syndr 21(suppl.1): S11–S17, 1999PubMedGoogle Scholar
  59. 59.
    Buchbinder SP, Holmberg SD, Scheer S et al: Combination antiretroviral therapy and incidence of AIDS-related malignancies. J Acquir Immune Defic Syndr 21(suppl.1): S23–S26, 1999PubMedGoogle Scholar
  60. 60.
    Sparano JA, Anand K, Desai J, et al: Effect of highly active antiretroviral therapy on the incidence of HIV-associated malignancies at an urban medical center. J Acquir Immune Defic Syndr 21(suppl.1): S18–S22, 1999PubMedGoogle Scholar
  61. 61.
    Pezzotti P, Dal Maso L, Serraino D, et al: Has the spectrum of AIDS-defining illnesses been changing since the introduction of new treatments and combination of treatments? J Acqui Immune Defic Syndr 20:515–516, 1999CrossRefGoogle Scholar
  62. 62.
    Pezzotti P, Serraino D, Rezza G, et al: The spectrum of AIDS-defining diseases: temporal trends in Italy prior to the use of highly active anti-retroviral therapies, 1982–1996. Int J Epidemiol 28:975–981, 1999PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Luigino Dal Maso
  • Diego Serraino
  • Silvia Franceschi

There are no affiliations available

Personalised recommendations